In this post hoc analysis, we evaluated the different response-assessment criteria and their ability to predict OS in patients with newly diagnosed glioblastoma treated with SOC and SOC + tumor lysate-charged autologous dendritic cells in a multicenter phase II clinical trial. Here, UBXN11 is linked to glioblastoma.